FXI-ASO
Jump to navigation
Jump to search
Indications
- prophylaxis for venous thromboembolism
- prevents DVT after total knee arthroplasty better than enoxaparin[1]
Dosage
- 200 mg QD
Adverse effects
- hemorrhage may be less than with enoxaparin
Mechanism of action
- antisense oligonucleotide
- reduces the level of factor XI
More general terms
- short interfering double-stranded RNA; antisense oligonucleotide (siRNA, microRNA, miRNA)
- anticoagulant
References
- ↑ Jump up to: 1.0 1.1 Buller HR et al Factor XI Antisense Oligonucleotide for Prevention of Venous Thrombosis N Engl J Med. Dec 7, 2014 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/25482425 <Internet> http://www.nejm.org/doi/full/10.1056/NEJMoa1405760
Flaumenhaft R Making (Anti)Sense of Factor XI in Thrombosis. N Engl J Med. Dec 7, 2014 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/25482334 <Internet> http://www.nejm.org/doi/full/10.1056/NEJMe1413874